Study cohort, n=16 504 | |||||
Age | Mean | SD | |||
67.6 | 12.0 | ||||
Sex | n | % | Medications used | n | % |
Male | 7865 | 47.7 | Metformin | 6504 | 39.4 |
Female | 8639 | 52.3 | Insulin | 3889 | 23.5 |
Race | n | % | ACEIs | 4261 | 25.8 |
Asian | 526 | 3.2 | ARBs | 4039 | 24.5 |
Black | 3490 | 21.1 | Corticosteroids | 1085 | 6.6 |
Hispanic | 3687 | 22.3 | Comorbidities | n | % |
White | 7589 | 46.0 | Neuropathy | 8074 | 48.9 |
Other/unknown | 1212 | 7.3 | Retinopathy | 6735 | 40.8 |
HbA1c bins | n | % | Nephropathy | 8567 | 51.9 |
6%–7% | 7212 | 43.7 | Coronary artery disease | 6449 | 39.1 |
7%–8% | 4466 | 27.1 | Stroke | 2302 | 13.9 |
8%–9% | 2360 | 14.3 | Hypertension | 15 614 | 94.6 |
9%–10% | 1215 | 7.4 | Obesity | 8797 | 53.3 |
10%–11% | 623 | 3.8 | Severity | n | % |
11%–12% | 347 | 2.1 | ICU usage | 2952 | 17.9 |
12%+ | 281 | 1.7 |
ACEI, ACE inhibitor; ARB, angiotensin receptor blocker; ICU, intensive care unit.